← Back to patent-cliff list
NS-050/NCNP-03
Tier C — Watch / tradeNS-050/NCNP-03
Nippon Shinyaku Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：Not applicable
Indications (approved)：Duchenne muscular dystrophy
Regional status
US
Phase II
2023-06-15
EU
-
China
-
Japan
Phase II
2024-09-18
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NS-050/NCNP-03?
Approved indications include: Duchenne muscular dystrophy.
When does the NS-050/NCNP-03 patent expire?
No public expiry year is available for NS-050/NCNP-03 yet; this page updates once verified.
How do I get a quote for NS-050/NCNP-03 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03